NCT01147822 - Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

367

Participants

Timeline

Start Date

May 19, 2010

Primary Completion Date

May 21, 2012

Study Completion Date

September 3, 2021

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Pazopanib

800 mg administered once daily orally continuous dosing

DRUG

Sunitinib

50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment

Trial Locations (21)

333

Novartis Investigative Site, Taoyuan

833

Novartis Investigative Site, Kaohsiung Hsien

10002

Novartis Investigative Site, Taipei

11217

Novartis Investigative Site, Taipei

40402

Novartis Investigative Site, Taichung

40705

Novartis Investigative Site, Taichung

100021

Novartis Investigative Site, Beijing

100036

Novartis Investigative Site, Beijing

100853

Novartis Investigative Site, Beijing

200032

Novartis Investigative Site, Shanghai

200127

Novartis Investigative Site, Shanghai

210002

Novartis Investigative Site, Nanjing

300060

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

510060

Novartis Investigative Site, Guangzhou

Unknown

Novartis Investigative Site, Beijing

301-721

Novartis Investigative Site, Daejeon

410-769

Novartis Investigative Site, Goyang-si, Gyeonggi-Do

120-752

Novartis Investigative Site, Seoul

135-710

Novartis Investigative Site, Seoul

138-736

Novartis Investigative Site, Seoul